Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Edmond S. Chan, MD"'
Autor:
Ann-Marie M. Schoos, MD, PhD, DMSc, Edmond S. Chan, MD, Tiffany Wong, MD, Stephanie C. Erdle, MD, Alanna Chomyn, MD, Lianne Soller, PhD, Raymond Mak, MD
Publikováno v:
World Allergy Organization Journal, Vol 17, Iss 2, Pp 100865- (2024)
Background: Oral immunotherapy is an effective treatment for food allergies; however, its use in clinical practice is limited by resources and lack of standardized protocols for foods other than peanut. Previous studies have suggested that shrimp has
Externí odkaz:
https://doaj.org/article/8bedcfe6f0074b28a3821ea55e6917c5
Autor:
Gilbert T. Chua, MBBS, Lianne Soller, PhD, Sandeep Kapur, MD, Mary McHenry, MD, Gregory A. Rex, MD, Victoria E. Cook, MSc, MD, Scott B. Cameron, MD, PhD, Edmond S. Chan, MD, Joanne Yeung, MD, Stephanie C. Erdle, MD
Publikováno v:
Journal of Allergy and Clinical Immunology: Global, Vol 3, Iss 1, Pp 100171- (2024)
Background: Previous studies support the effectiveness of sesame oral immunotherapy (S-OIT) in patients >4 years old using maintenance doses of 1200 mg protein. However, tahini is often not palatable to children, and high-maintenance doses may not be
Externí odkaz:
https://doaj.org/article/419f5832508a49019ca3476a94bd4b3d
Autor:
Uliana Kovaltchouk, MD, FRCPC, Samira Jeimy, MD, PhD, FRCPC, Lianne Soller, PhD, Kara Robertson, MD, FRCPC, Elissa M. Abrams, MD, FRCPC, Scott B. Cameron, MD, PhD, FRCPC, Harold Kim, MD, FRCPC, Edmond S. Chan, MD, FRCPC
Publikováno v:
Journal of Allergy and Clinical Immunology: Global, Vol 2, Iss 2, Pp 100080- (2023)
Background: The safety of pediatric food oral immunotherapy (Ped-OIT) has been depicted by some as less favorable than subcutaneous immunotherapy (SCIT) owing to the increased number of serious adverse events requiring epinephrine. A review of real-w
Externí odkaz:
https://doaj.org/article/2ea0d9c8a5a74ec9a20753e5e249543e
Autor:
Duva Karunakaran, BSc, Edmond S. Chan, MD, Qian Zhang, Jeffrey N. Bone, Stuart Carr, MD, Sandeep Kapur, MD, Gregory A. Rex, MD, Mary McHenry, MD, Scott B. Cameron, MD, PhD, Victoria E. Cook, MD, Sara Leo, MD, Tiffany Wong, MD, Thomas V. Gerstner, MD, Joanne Yeung, MD, Elissa M. Abrams, MD, Raymond Mak, MD, Stephanie C. Erdle, MD, Lianne Soller, PhD
Publikováno v:
Journal of Allergy and Clinical Immunology: Global, Vol 2, Iss 2, Pp 100094- (2023)
Background: An understanding of how patient characteristics such as age, baseline peanut-specific IgE, and atopic comorbidities may influence potential safety outcomes during peanut oral immunotherapy (P-OIT) could aid in shared decision making betwe
Externí odkaz:
https://doaj.org/article/82021a3786864d6580297d82a8049062